Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the course and burden of adverse drug reactions over time attributed to using TNFα-inhibitors in patients with inflammatory rheumatic diseases

Next Previous
Search
Trial Profile

Assessment of the course and burden of adverse drug reactions over time attributed to using TNFα-inhibitors in patients with inflammatory rheumatic diseases

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
  • Indications Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions

    • Most Recent Events

    • 30 Jun 2022 New trial record
    • 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top